Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lapatinib on JTZ-951 PK in ESRD
NCT02581124Phase 1Completed
- Sponsor
- Akros Pharma Inc.
- Start
- Oct 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enarodustat in anemia of chronic kidney disease (CKD-A), sponsored by Akros Pharma Inc. Primary endpoints: Maximum Concentration at 10 days, Time to Maximum Concentration at 10 days and 3 more. Started Oct 2015; status: completed.
02
Drugs
enarodustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02581124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581124.